All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Targeted Treatments Shift the Paradigm of Advanced BTC

May 5th 2025

During the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, an OncLive Peer Exchange® featured insights from expert investigators in the field of BTC.

Ventana TROP2 (EPR20043) RxDx Device Receives FDA Breakthrough Device Designation for Dato-DXd Selection in NSCLC

May 5th 2025

The AI-driven companion diagnostic device Ventana TROP2 (EPR20043) RxDx has received FDA breakthrough device designation in NSCLC.

Five Under 5: Top Oncology Videos for the Week of 4/27

May 4th 2025

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

Mixed Trial Results Underscore Challenges of Adjuvant TKI, IO Regimens in RCC

May 4th 2025

Helen Moon, MD, discusses the current and potential role of TKIs and immunotherapy regimens as adjuvant therapy in renal cell carcinoma.

The OncFive: Top Oncology Articles for the Week of 4/27

May 3rd 2025

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

FDA Grants Fast Track Designation to BI-1808 in Select Cutaneous T-Cell Lymphoma

May 3rd 2025

BI-1808 has received FDA fast track designation for the treatment of patients with select cutaneous T-cell lymphoma subtypes.

Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval

May 2nd 2025

Arielle Heeke, MD, highlights the role of adjuvant abemaciclib and ribociclib in patients with HR-positive, HER2-negative, early breast cancer.

Zongertinib Could Alter SOC in HER2-Mutated Advanced NSCLC

May 2nd 2025

John V. Heymach, MD, PhD, discusses updated findings from the phase 1b Beamion LUNG-1 trial of zongertinib in HER2-mutated advanced NSCLC.

5-Year Phase 2 Data Show 0% Recurrence Rate After Surgery Omission in Select Patients With Invasive Breast Cancer

May 2nd 2025

No recurrences, disease-free survival events, or deaths were reported in select patients with breast cancer who had surgery omitted.

Fox Chase Cancer Center Researcher Adria Hasan Honored With Scholar-in-Training Award From American Association for Cancer Research

May 2nd 2025

Fox Chase Cancer Center researcher Adria Hasan honored with scholar-in-training award from American Association for Cancer Research.

Zurletrectinib Receives Priority Review from NMPA for NTRK Gene Fusion+ Advanced Solid Tumors

May 2nd 2025

A priority review was granted to zurletrectinib in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL

May 2nd 2025

An sBLA seeking the approval of epcoritamab plus rituximab and lenalidomide for relapsed/refractory FL is planned to be submitted to the FDA.

Oncology Experts Highlight Top Takeaways From the 2025 AACR Annual Meeting

May 2nd 2025

Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting.

RP1 Plus Nivolumab Represents the Next Frontier of Oncolytic Virus–Based Therapy for Melanoma

May 2nd 2025

Anna C. Pavlick, BSN, MSc, DO, MBA, discusses data for RP1 plus nivolumab and the evolving treatment landscape in advanced melanoma.

Less Is More With Advanced Surgical Approaches in Early-Stage NSCLC

May 2nd 2025

Alexis Chidi, MD, PhD, MSPH, details the evolution of surgical approaches in early-stage lung cancer, including wedge resections and segmentectomies.

Revisit Every OncLive On Air Episode From April 2025

May 1st 2025

Read a recap of the episodes of OncLive On Air that aired in April 2025.

Patient Selection Is Crucial for Treatment Decisions in Metastatic Melanoma After PD-1 Inhibition

May 1st 2025

Stergios Moschos, MD, discusses his approach to selecting from the available agents in metastatic melanoma after first-line PD-1 inhibition.

AACR: New CAR T-Cell Therapy Benefits Patients With Advanced Thyroid Cancers

May 1st 2025

Results from the first-in-human phase I trial were presented at the 2025 AACR Annual Meeting.

FDA Issues CRL to TLX101-CDx for Glioma Imaging

May 1st 2025

The FDA issued a complete response letter to the new drug application seeking the approval of TLX101-CDx as an imaging agent for glioma.

KN026 Plus Chemo Improves PFS in Pretreated HER2+ Gastric/GEJ Cancer

May 1st 2025

KN026 plus chemotherapy significantly improves PFS in second-line and later HER2-positive advanced gastric/GEJ cancer.